Clinical Trials
Closed
Phase
Accrual
57%
SWOG Clinical Trial Number
S1400B
A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDY OF GDC-0032 (TASELISIB) FOR PREVIOUSLY TREATED PI3K POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
Status Notes
Effective 11:59 p.m. Pacific Time on December 12, 2016, S1400B will be permanently closed to accrual.
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
12-12-2016
Closed
Phase
Accrual
81%
SWOG Clinical Trial Number
S1400D
A BIOMARKER DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDY OF AZD4547 FOR PREVIOUSLY TREATED FGFR-POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
Status Notes
Effective 11:59 p.m. Pacific Time on October 31, 2016, the following sub-study will be permanently closed to accrual.
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
10-31-2016
Closed
Phase
Accrual
91%
SWOG Clinical Trial Number
S1400C
A BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER - A PHASE II STUDYOF PALBOCICLIB FOR PREVIOUSLY TREATED CELL CYCLE GENE ALTERATION POSITIVE PATIENTS WITH STAGE IV SQUAMOUS CELL LUNG CANCER
Status Notes
Effective 11:59 p.m. Pacific Time on September 1, 2016, S1400C will be permanently closed to accrual.
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
S1400E
Phase II/III Randomized Study of Rilotumumab plus Erlotinib versus Erlotinib as Second Line Therapy For Biomarker Selected Patients With Squamous Cell Lung Cancer
Status Notes
This sub-study will be permanently closed to accrual on 11/24/2014 at 2:00 p.m. Pacific
Research Committee(s)
Lung Cancer
Activated
06-15-2014
Closed
11-25-2014
Closed
Phase
Accrual
4%
SWOG Clinical Trial Number
S1222
Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial In Postmenopausal Patients With Hormone-Receptor Positive Stage IV Breast Cancer.
Status Notes
NOTE: This study is permanently closed to accrual effective 10/15/2015.
Research Committee(s)
Breast Cancer
Activated
05-09-2014
Closed
10-15-2015
ClinicalTrials.gov Registry Number
NCT02137837
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1312
A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Lymphoblastic Leukemia (including B-ALL, Mixed Phenotypic Leukemia and Burkitt's Leukemia)
Status Notes
Expansion cohort activated to accrual (Dose Level 5) effective10/25/17.
NOTE: This study is open to limited institutions only.
NOTE: This study requires slot reservation prior to registration.
NOTE: This study is open to limited institutions only.
NOTE: This study requires slot reservation prior to registration.
Research Committee(s)
Leukemia
Activated
04-01-2014
Closed
08-02-2019
ClinicalTrials.gov Registry Number
NCT01925131
Closed
Phase
Accrual
60%
SWOG Clinical Trial Number
S1310
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
02-15-2014
Closed
05-15-2015
ClinicalTrials.gov Registry Number
NCT02042443
Closed
Phase
Accrual
73%
SWOG Clinical Trial Number
S1313
A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma
Status Notes
This study is permanently closed effective 07/01/2017.
Research Committee(s)
Gastrointestinal Cancer
Activated
01-06-2014
ClinicalTrials.gov Registry Number
NCT01959139
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1304
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
Status Notes
Effective 5/15/16, this study was permanently closed to accrual.
Research Committee(s)
Myeloma
Activated
10-18-2013
Closed
05-15-2016
ClinicalTrials.gov Registry Number
NCT01903811
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1207
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.
Status Notes
S1207 will be permanently closed to accrual effective May 1, 2019 at 11:59 p.m. Pacific Time.
Effective 12/15/18, with the distribution of Revision #11 (Version Date 10/24/18), procedures for planned unblinding are now included in Section 7.5 of the protocol.
Effective 12/15/18, with the distribution of Revision #11 (Version Date 10/24/18), procedures for planned unblinding are now included in Section 7.5 of the protocol.
Research Committee(s)
Breast Cancer
Activated
09-03-2013
Closed
05-01-2019
ClinicalTrials.gov Registry Number
NCT01674140
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1204
A Sero-Epidemiologic Survey and Cost-effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients
Status Notes
This study closed to patient accrual 2/15/17.
Research Committee(s)
Cancer Care Delivery
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Leukemia
Lung Cancer
Lymphoma
Melanoma
Myeloma
Activated
08-29-2013
Closed
02-15-2017
ClinicalTrials.gov Registry Number
NCT01946516
Closed
Phase
Accrual
39%
SWOG Clinical Trial Number
S1221
"Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer."
Status Notes
The study referenced above was temporarily closed to accrual on 10/31/2016.
Due to drug supply on this study, the study will be switched from temporarily closed to permanently closed with the same status date of 10/31/2016.
Due to drug supply on this study, the study will be switched from temporarily closed to permanently closed with the same status date of 10/31/2016.
Research Committee(s)
Melanoma
Gastrointestinal Cancer
Leukemia
Activated
07-01-2013
ClinicalTrials.gov Registry Number
NCT01902173
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S1202
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer
Status Notes
This protocol will be permanently closed to accrual effective 10/1/15.
Research Committee(s)
Symptom Control and Quality of Life
Breast Cancer
Activated
05-15-2013
Closed
10-01-2015
ClinicalTrials.gov Registry Number
NCT01598298
Closed
Phase
Accrual
91%
SWOG Clinical Trial Number
S0820
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)"
Research Committee(s)
Prevention & Epidemiology
Gastrointestinal Cancer
Activated
03-01-2013
ClinicalTrials.gov Registry Number
NCT01349881
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1216
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
Research Committee(s)
Genitourinary Cancer
Activated
03-01-2013
Closed
07-15-2017
ClinicalTrials.gov Registry Number
NCT01809691
Closed
Phase
Accrual
96%
SWOG Clinical Trial Number
S1203
A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Status Notes
S1203 will permanently close to accrual on 11/4/15 at 11:59pm Pacific Time.
Research Committee(s)
Leukemia
Activated
12-15-2012
Closed
11-04-2015
ClinicalTrials.gov Registry Number
NCT01802333
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1211
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Status Notes
This study was temporarily closed to accrual on June 2, 2016 at 11:59 p.m. Pacific.
Research Committee(s)
Myeloma
Activated
10-12-2012
ClinicalTrials.gov Registry Number
NCT01668719
Closed
Phase
Accrual
71%
SWOG Clinical Trial Number
S1107
Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma
Research Committee(s)
Genitourinary Cancer
Activated
08-20-2012
Closed
05-29-2014
ClinicalTrials.gov Registry Number
NCT01688973
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S1115
Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs. mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy
Research Committee(s)
Gastrointestinal Cancer
Activated
08-15-2012
Closed
05-15-2014
ClinicalTrials.gov Registry Number
NCT01658943
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
S1105
Randomized Trial Of A Text-Messaging Intervention To Reduce Early Discontinuation Of Adjuvant Aromatase Inhibitor Therapy In Women With Early Stage Breast Cancer
Research Committee(s)
Cancer Care Delivery
Breast Cancer
Activated
03-27-2012
Closed
09-15-2013
ClinicalTrials.gov Registry Number
NCT01515800